Work

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Year: 2017

Type: article

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.2822.2822

Authors: Pallawi Torka, Seema A. Bhat, Kelvin P. Lee, Alan D. Hutson, Jenna Nichols, Angela Kader, Cory Mavis, AnneMarie W. Block, Sheila N.J. Sait, Bora E. Baysal, Fadi Habib, Vishala T. Neppalli, Francisco J. Hernandez‐Ilizaliturri

Institution: Roswell Park Comprehensive Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3041107239

FWCI: 0.371

Cites:

Cited by: 3

Related to: 20